European Commission approves Tiwa Ajovy preventive treatment for migraines
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Israel'sPharmaceutical(http://giant Teva announced that the European Commission (EC) has approved Ajovy (fremanezumab) 225mg injection pre-charged syringe for adult patients with migraines at least four days a month, the prevention of the treatment of migrainesAbout Ajovy
Ajovy is a monoclonal antibodydrug(http://that targets the target calcitonin-related gene peptide (CGRP) ligand and blocks its binding to the receptorCGRP is a neuropeptide that has been shown to be released during a migraine attack and is thought to be a trigger for a migraine attackAt present, CGRP has become a hot target for the development of migraine drugsSo far, three anti-CGRP treatments have been approved in the United States and the European Union, including Novartis/Amin's Aimovig, Lilly's Emgality and Teva's Ajovy (fremanezumab)In terms of medication, Aimovig and Emgality are both injected once a month, while Ajovy is given a monthly or once-every-3 months subcutaneous injections, which are more convenient and will provide patients with a differentiated treatment optionIn addition to the three approved antibody drugs mentioned above, The single anti-drug eptinezumab (intravenously per 3 months) of the http://of The AlderCompany submitted an application in the United States at the end of February this year, with a response rate of up to 100 percent in some patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
